Powered by: Motilal Oswal

News

Dr. Reddy`s Laboratories gains on launching Saxagliptin and Metformin Hydrochloride Extended-Release Tablets Dr. Reddy's Laboratories is currently trading at Rs. 5849.65, up by 8.05 points or 0.14% from its previous closing of Rs. 5841.60 on the BSE. The scrip opened at Rs. 5830.90 and has touched a high and low of Rs. 5881.05 and Rs. 5821.90 respectively. So far 3829 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5916.85 on 10-Aug-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022. Last one week high and low of...
Dr. Reddy`s Laboratories gains on launching Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
Dr. Reddy`s Laboratories gains on launching Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
Source: Accord Fintech
11/08/2023 12:15:17 PM
Dr. Reddy`s Laboratories gains on reporting 18% rise in Q1 consolidated net profit Dr. Reddy's Laboratories is currently trading at Rs. 5551.05, up by 74.55 points or 1.36% from its previous closing of Rs. 5476.50 on the BSE. The scrip opened at Rs. 5535.00 and has touched a high and low of Rs. 5613.85 and Rs. 5425.00 respectively. So far 36005 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5613.85 on 27-Jul-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022. Last one week high and low ...
Dr. Reddy`s Laboratories gains on reporting 18% rise in Q1 consolidated net profit
Dr. Reddy`s Laboratories gains on reporting 18% rise in Q1 consolidated net profit
Source: Accord Fintech
27/07/2023 2:43:19 PM
India`s Dr.Reddy`s posts 18% rise in Q1 profit on strong generic drugs sales Indian pharma giant Dr Reddy's Laboratories reported an 18% rise in its first-quarter profit on Wednesday, propelled by strong performance at its core businesses of generic drugs especially in North America. The company's consolidated profit rose to 14.03 billion rupees ($171.09 million), from 11.88 billion rupees last year.
India`s Dr.Reddy`s posts 18% rise in Q1 profit on strong generic drugs sales
India`s Dr.Reddy`s posts 18% rise in Q1 profit on strong generic drugs sales
Source: Reuters
26/07/2023 4:08:15 PM
Stock Picks : Dr. Reddy Laboratories Ltd and National Aluminium Ltd By ICICI Direct Dr. Reddy Laboratories Ltd Buy Dr. Reddy Laboratories Ltd @5189-5195; Target 5248.00; Stop Loss 5159.00   National Aluminium Company Ltd Buy National Aluminium Company Ltd @85.00-85.50; Target 86.90; Stop Loss 84.60       To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Regi...
Stock Picks : Dr. Reddy Laboratories Ltd and National Aluminium Ltd By ICICI Direct
Stock Picks : Dr. Reddy Laboratories Ltd and National Aluminium Ltd By ICICI Direct
Source: ICICI Direct
13/07/2023 10:51:42 AM
Dr Reddy`s Laboratories trades higher on eyeing to enhance presence in emerging segments like nutraceuticals Dr. Reddy's Laboratories is currently trading at Rs. 5176.55, up by 12.35 points or 0.24% from its previous closing of Rs. 5164.20 on the BSE. The scrip opened at Rs. 5111.45 and has touched a high and low of Rs. 5190.45 and Rs. 5111.45 respectively. So far 2470 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5272.35 on 07-Jul-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022. Last one week high and low o...
Dr Reddy`s Laboratories trades higher on eyeing to enhance presence in emerging segments like nutraceuticals
Dr Reddy`s Laboratories trades higher on eyeing to enhance presence in emerging segments like nutraceuticals
Source: Accord Fintech
12/07/2023 12:21:07 PM
Dr Reddy`s rises on foraying into child nutrition space with launch of gummies Dr. Reddy's Laboratories is currently trading at Rs. 5243.10, up by 11.45 points or 0.22% from its previous closing of Rs. 5231.65 on the BSE. The scrip opened at Rs. 5248.95 and has touched a high and low of Rs. 5272.35 and Rs. 5042.65 respectively. So far 3880 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,272.35  on 06-Jul-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022. Last one week high an...
Dr Reddy`s rises on foraying into child nutrition space with launch of gummies
Dr Reddy`s rises on foraying into child nutrition space with launch of gummies
Source: Accord Fintech
7/07/2023 11:37:08 AM
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,680 - Motilal Oswal Financial Services Robust show in FY23; but outlook subdued We assessed the 20F annual filing of Dr. Reddy’s Lab (DRRD) to understand its FY23 segmental performance and capital utilization in further details. * DRRD exited FY23 on a strong note driven by healthy sales growth (13.5% YoY), better profitability (460bp margin expansion) and solid earnings growth (39% YoY). * Further, the company optimized its product offerings in India/North America by selling certain brands for INR5b and acquiring b...
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,680 - Motilal Oswal Financial Services
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,680 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
26/06/2023 1:10:10 PM
Dr. Reddy's Laboratories zooms on entering into trade generics business in India Dr. Reddy's Laboratories is currently trading at Rs. 5007.45, up by 107.75 points or 2.20% from its previous closing of Rs. 4899.70 on the BSE. The scrip opened at Rs. 4901.35 and has touched a high and low of Rs. 5015.00 and Rs. 4901.35 respectively. So far 50358 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5021.15 on 19-Jun-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022. Last one week high and low...
Dr. Reddy's Laboratories zooms on entering into trade generics business in India
Dr. Reddy's Laboratories zooms on entering into trade generics business in India
Source: Accord Fintech
23/06/2023 4:13:58 PM
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost Cipla Ltd, India's third-largest drugmaker by sales, reported a 45.2% increase in fourth-quarter profit on Friday, driven by strength in its key domestic and North American drugs business. Shares of the company, which manufactures generic versions of respiratory drugs Advair and Albuterol, were flat after the results but closed 0.7% lower in their second straight session of losses. Cipla's consolidated net profit jumped to 5.26 billion rupees in the quarter ended March 31 from 3...
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost
India`s Cipla posts 45% jump in Q4 profit on domestic drugs business boost
Source: Reuters
12/05/2023 4:44:18 PM
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,500 - Motilal Oswal Financial Services * Adj. for divestment of brands in the domestic formulation (DF) segment, Dr. Reddy’s Labs (DRRD) recorded in-line sales in 4QFY23. However, it posted lower-than-expected EBITDA/PAT due to higher opex. DRRD delivered the highest-ever annual earnings in FY23, led by strong traction in g-Revlimid. * We reduce our earnings estimates for FY24/FY25 by 7%/7.5%, factoring in 1) higher SGA expenses, 2) prolonged slowdown in the CIS business, and 3) some price erosion in export markets. We co...
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,500 - Motilal Oswal Financial Services
Neutral Dr Reddy's Laboratories Ltd For Target Rs.4,500 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services
11/05/2023 2:40:40 PM
India's Dr Reddy's Labs posts 11-fold jump in Q4 profit BENGALURU - Indian drugmaker Dr Reddy's Laboratories Ltd reported nearly an eleven-fold surge in fourth-quarter profit on Wednesday, driven by higher sales from its mainstay generic drugs business in North America. The Hyderabad-based company's consolidated profit rose to 9.59 billion rupees in the three months ended March 31, compared with 875 million rupees a year earlier. The profit, however, missed analysts' expectations of 9.74 billion rupees, according to Refinitiv IBE...
India's Dr Reddy's Labs posts 11-fold jump in Q4 profit
India's Dr Reddy's Labs posts 11-fold jump in Q4 profit
Source: Reuters
10/05/2023 7:17:17 PM
Stock Picks : Dr Reddy Laboratories Ltd and Canara Bank Ltd By ICICI Direct Dr Reddy Laboratories Ltd Dr Reddy Laboratories Ltd  @ 4454-4458CMP 4474.95 Stop Loss 4424.00 Target 4509.00        United Spirits Ltd  United Spirits Ltd @ 72-774 CMP 776.30 Stop Loss 766.70 Target 783.80         To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icici...
Stock Picks : Dr Reddy Laboratories Ltd and Canara Bank Ltd By ICICI Direct
Stock Picks : Dr Reddy Laboratories Ltd and Canara Bank Ltd By ICICI Direct
Source: ICICI Direct
23/03/2023 10:42:30 AM
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million Indian drugmaker Eris Lifesciences Ltd said on Thursday it had bought nine dermatology brands from Dr. Reddy's Laboratories Ltd in a 2.75 billion rupees ($33.24 million) deal, to expand in the cosmetic dermatology business. The deal, to be paid in cash, is expected to be completed on or before March 31, Eris said in a stock exchange filing. Eris and Dr. Reddy's did not immediately respond to Reuters' requests seeking the names of the dermatology brands. The deal comes two...
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million
India's Eris buys nine dermatology brands from Dr. Reddy's for $33 million
Source: Reuters
16/03/2023 3:15:53 PM
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,890 - JM Financial Institutional Securities Healthy FCFF DDRD delivered earnings well ahead of our estimates largely driven by new launches in the US, India and EMs particularly Russia. We believe the base business along with new launches has grown the US sales to USD 375mn. We believe gRevlimid contribution of USD 125- 130mn allows us to see the global generics gross margin soaring to c.60%. As indicated earlier, PSAI segment outperformed expectations with 18% gross margins (vs.4% QoQ) and is expected to grow hereon. Cidmus has bee...
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,890 - JM Financial Institutional Securities
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,890 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
9/03/2023 12:43:54 PM
Buy Dr. Reddy`s Laboratories Ltd For Target Rs. 5,800 - Anand Rathi Share and Stock Brokers Q3-FY23 Result Update * Dr. Reddy’s Laboratories Ltd. revenue for the quarter stood at ?67,898 million, grew by 27.9% YoY on consolidated basis. Segment wise revenue from Global Generic, Pharmaceutical services and active ingredients (PSAI) and Others segment stood at ? 59,200 million ?7,800 million and ?700 million, grew by 33%, 7% and (51%) YoY respectively. * Revenue from Gobal generic business was primarily driven by new product launches, increase in volumes of their base busi...
Buy Dr. Reddy`s Laboratories Ltd For Target Rs. 5,800 - Anand Rathi Share and Stock Brokers
Buy Dr. Reddy`s Laboratories Ltd For Target Rs. 5,800 - Anand Rathi Share and Stock Brokers
Source: Anand Rathi Share and Stock Brokers Ltd
6/03/2023 12:23:11 PM
Dr. Reddy's acquires Mayne Pharma's US prescription portfolio for $105 mn Indian pharma major, Dr. Reddy's Laboratories Ltd, through its subsidiary has inked an agreement to acquire the US generic prescription product portfolio of the Australia-based, Mayne Pharma Group Limited, for consideration of about $105 million. According to Dr. Reddy's, $90 million will be paid upfront in cash and there will be contingent payments of up to $15 million, towards inventory and credits for certain accrued channel liabilities to be determined on the closing date. T...
Dr. Reddy's acquires Mayne Pharma's US prescription portfolio for $105 mn
Dr. Reddy's acquires Mayne Pharma's US prescription portfolio for $105 mn
Source: IANS
27/02/2023 12:58:49 PM
Dr. Reddy`s Laboratories surges on reporting 75% rise in Q3 consolidated net profit Dr. Reddy's Laboratories is currently trading at Rs. 4320.15, up by 115.60 points or 2.75% from its previous closing of Rs. 4204.55 on the BSE. The scrip opened at Rs. 4293.35 and has touched a high and low of Rs. 4382.35 and Rs. 4265.30 respectively. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 4,645.55 on 2-November-2022 and a 52 week low of Rs. 366.05 on 4-March-2022. Last one week high and low of the scrip stood at Rs. 4400.00 and Rs. ...
Dr. Reddy`s Laboratories surges on reporting 75% rise in Q3 consolidated net profit
Dr. Reddy`s Laboratories surges on reporting 75% rise in Q3 consolidated net profit
Source: Accord Fintech
27/01/2023 11:45:35 AM
Stock Picks - Dr. Reddy Ltd And Can Fin Homes Ltd By ICICI Direct Dr. Reddy Ltd Buy Dr. Reddy Ltd @ 4517-4525 CMP 4477.00 Stop Loss 1999.70 Target 4561/4604.00   Can Fin Homes Ltd Buy Can Fin Homes Ltd @ 502-505 CMP 507.30 Stop Loss 508.70 Target 498.50/493.50   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ00...
Stock Picks - Dr. Reddy Ltd And Can Fin Homes Ltd By ICICI Direct
Stock Picks - Dr. Reddy Ltd And Can Fin Homes Ltd By ICICI Direct
Source: ICICI Direct
3/11/2022 11:28:59 AM
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,960 - JM Financial Institutional Securities Dr Reddy’s delivered a strong 2Q much ahead of street estimates (46% PAT beat) and our estimates (36% beat). The outperformance was led by gRevlimid, PLI benefits and product mix. Their core EBITDA margins improved significantly QoQ, even excluding gRevlimid (23- 24%). Management maintains EBITDA margin guidance of 25% on a sustainable basis as we expect many levers to aid expansion (such as PSAI margin recovery) and further improvement in performance 2H onwards. 2Q has delivered steady...
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,960 - JM Financial Institutional Securities
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,960 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
31/10/2022 3:15:44 PM
WEF recognises Dr Reddy's Hyderabad factory part of global lighthouse network  Pharma major Dr Reddy's Laboratories on Tuesday announced that the World Economic Forum (WEF) has recognised its largest manufacturing facility in Bachupally, Hyderabad, as part of its global lighthouse network. Lighthouses are factories leading the way in Fourth Industrial Revolution (Industry 4.0 or 4IR) technologies to drive impact in productivity, workforce engagement, sustainability, and supply chain resilience. "The journey of our facility started four years ago wit...
WEF recognises Dr Reddy's Hyderabad factory part of global lighthouse network
WEF recognises Dr Reddy's Hyderabad factory part of global lighthouse network
Source: IANS
12/10/2022 9:26:30 AM
Stock Picks - Dr Reddy Laboratories Ltd and Larsen Toubro Ltd By ICICI Direct Dr Reddy Laboratories Ltd Buy Dr Reddy Laboratories Ltd @ 4378-4382 CMP 4397.55 Stop Loss 4339.00 Target 4424/4447    Larsen Toubro Ltd Buy Larsen Toubro Ltd @ 1904-1906 CMP 1912.95 Stop Loss 1884.40 Target 1924/1945   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Disclaimer.html SEBI Registration number INZ000183631 ...
Stock Picks - Dr Reddy Laboratories Ltd and Larsen Toubro Ltd By ICICI Direct
Stock Picks - Dr Reddy Laboratories Ltd and Larsen Toubro Ltd By ICICI Direct
Source: ICICI Direct
7/10/2022 11:04:40 AM
Buy Dr Reddy`s Laboratories Ltd For Target Rs.5,000 - Motilal Oswal Financial Services Multiple one-offs hurt 1QFY23 profitability… …but outlook remains intact in key segments * Dr. Reddy’s Labs (DRRD) delivered in-line operational performance in 1QFY23, adjusting for the multiple non-recurring factors. Muted performances in North America (NAM), Pharmaceutical services & ingredient (PSAI) and Russia segment was offset by domestic formulation (DF) segment. Niche launches are likely to revive sales prospects for NAM from 2HFY23 onwards. * We maint...
Buy Dr Reddy`s Laboratories Ltd For Target Rs.5,000 - Motilal Oswal Financial Services
Buy Dr Reddy`s Laboratories Ltd For Target Rs.5,000 - Motilal Oswal Financial Services
Source: Motilal Oswal Financial Services Ltd
8/09/2022 12:43:14 PM
Stock Picks - Axis Bank Ltd and Dr. Reddy`s Laboratories Ltd By ICICI Direct Axis Bank Ltd Buy Axis Bank Ltd @ 740.00-742.00 CMP 745.55 Stop Loss 734.3 Target 747.00/753.00   Dr. Reddy's Laboratories Buy Dr. Reddy's Laboratories @ 4204.00-4210.00 CMP 4223.35 Stop Loss 4176.70 Target 4237.00/4263.00   To Read Complete Report & Disclaimer Click Here   Please refer disclaimer at https://secure.icicidirect.com/Content/StaticData/Discla...
Stock Picks - Axis Bank Ltd and Dr. Reddy`s Laboratories Ltd By ICICI Direct
Stock Picks - Axis Bank Ltd and Dr. Reddy`s Laboratories Ltd By ICICI Direct
Source: ICICI Direct
10/08/2022 10:07:55 AM
Dr. Reddy`s Labs Q1 net profit up 20.83% at Rs 499.50 cr The company reported standalone net profit of Rs 499.50 crore for the quarter ended June 30, 2022 as compared to Rs 413.40 crore in the same period last year, registering a year-on-year growth of 20.83 per cent. Net revenue of the company rose by 5.30 per cent at Rs 3,615.60 crore in April-June quarter of this fiscal as against Rs 3,433.50 crore in the corresponding period last year. During April-June quarter, operating expenses increased by 6.25 per cent to Rs 3,051.10 crore from Rs 2,871.60...
Dr. Reddy`s Labs Q1 net profit up 20.83% at Rs 499.50 cr
Dr. Reddy`s Labs Q1 net profit up 20.83% at Rs 499.50 cr
Source: Dion Global Solutions Ltd
29/07/2022 9:09:55 AM
Dr. Reddy`s jumps on launching Bortezomib for Injection in US Market Dr. Reddy’s Laboratories is currently trading at Rs. 4258.00, up by 46.50 points or 1.10% from its previous closing of Rs. 4211.50 on the BSE. The scrip opened at Rs. 4212.00 and has touched a high and low of Rs. 4265.00 and Rs. 4164.50 respectively. So far 3521 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,445.00 on 27-Jul-2021 and a 52 week low of Rs. 3,655.00 on 04-Mar-2022. Last one week high and l...
Dr. Reddy`s jumps on launching Bortezomib for Injection in US Market
Dr. Reddy`s jumps on launching Bortezomib for Injection in US Market
Source: Accord Fintech
27/07/2022 2:09:00 PM
JB Chemicals surges on acquiring portfolio of brands from Dr Reddy`s JB Chemicals & Pharmaceuticals is currently trading at Rs. 1691.90, up by 12.15 points or 0.72% from its previous closing of Rs. 1679.75 on the BSE. The scrip opened at Rs. 1685.05 and has touched a high and low of Rs. 1699.00 and Rs. 1659.25 respectively. So far 1547 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1984.75 on 28-Sep-2021 and a 52 week low of Rs. 1339.05 on 16-Jun-2022. Last one week high and...
JB Chemicals surges on acquiring portfolio of brands from Dr Reddy`s
JB Chemicals surges on acquiring portfolio of brands from Dr Reddy`s
Source: Accord Fintech
22/07/2022 11:36:02 AM
JB Chemicals inches up on getting nod to acquire four paediatric brands from Dr Reddy's Laboratories JB Chemicals & Pharmaceuticals is currently trading at Rs. 1563.10, up by 7.65 points or 0.49% from its previous closing of Rs. 1555.45 on the BSE. The scrip opened at Rs. 1590.00 and has touched a high and low of Rs. 1590.00 and Rs. 1550.60 respectively. So far 934 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1984.75 on 28-Sep-2021 and a 52 week low of Rs. 1339.05 on 16-Jun-2022. Last one week high and l...
JB Chemicals inches up on getting nod to acquire four paediatric brands from Dr Reddy's Laboratories
JB Chemicals inches up on getting nod to acquire four paediatric brands from Dr Reddy's Laboratories
Source: Accord Fintech
30/06/2022 1:31:59 PM
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,960 - ICICI Direct To embark upon Horizon 2 by leveraging on Horizon 1 About the stock: Dr Reddy’s (DRL) portfolio includes pharmaceutical generics, APIs, custom pharmaceutical services, biosimilar and complex formulations   Investor Meet Takeaways: Dr Reddy’s is embarking on the next phase of its strategy in alignment with changing dynamics of industry, emerging opportunities. * The goal is to leverage Horizon 1 business growth levers and drive productivity to invest in Horizon 2 b...
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,960 - ICICI Direct
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,960 - ICICI Direct
Source: ICICI Direct
28/06/2022 12:50:47 PM
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,685 - JM Financial Institutional Securities Ushering into a new era of growth The Investor Day of Dr Reddy’s unveils a sustainable, affordable, patient-centric and innovation driven vision for their future growth. The global environment is evolving to medical science approaching healthcare needs more holistically. The disruption in global economies and intense competition in traditional generics business offers opportunities to focus on execution priorities like leadership in existing space, operational excellence with continu...
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,685 - JM Financial Institutional Securities
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,685 - JM Financial Institutional Securities
Source: JM Financial Institutional Securities Ltd
23/06/2022 11:54:49 AM
Dr. Reddy's Laboratories gains as its arm inks exclusive global license agreement with Olema Dr. Reddy’s Laboratories is currently trading at Rs. 4330.50, up by 4.40 points or 0.10% from its previous closing of Rs. 4326.10 on the BSE. The scrip opened at Rs. 4326.00 and has touched a high and low of Rs. 4344.00 and Rs. 4283.80 respectively. So far 6365 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5,613.65 on 07-Jul-2021 and a 52 week low of Rs. 3,655.00 on 04-Mar-2022. Last one week high and lo...
Dr. Reddy's Laboratories gains as its arm inks exclusive global license agreement with Olema
Dr. Reddy's Laboratories gains as its arm inks exclusive global license agreement with Olema
Source: Accord Fintech
10/06/2022 12:34:21 PM
Torrent Pharma rises on entering into agreement with Dr Reddy's Laboratories Torrent Pharma is currently trading at Rs. 2905.00, up by 4.10 points or 0.14% from its previous closing of Rs. 2900.90 on the BSE. The scrip opened at Rs. 2927.00 and has touched a high and low of Rs. 2933.00 and Rs. 2879.10 respectively. So far 4240 shares were traded on the counter. The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3304.45 on 31-Dec-2021 and a 52 week low of Rs. 2485.00 on 12-May-2022. Last one week high and low of the scrip sto...
Torrent Pharma rises on entering into agreement with Dr Reddy's Laboratories
Torrent Pharma rises on entering into agreement with Dr Reddy's Laboratories
Source: Dion Global Solutions Ltd
27/05/2022 11:01:39 AM
Key News - Tata Sons, Dr Reddy's Labs, APM Terminals Pipavav, Maruti Suzuki India, MakeMyTrip , Waaree, By ARETE Securities Key News Ratan Tata, Tata Sons welcome SC dismissal of review petition by SP Group Veteran industrialist Ratan Tata and Tata Sons on Thursday welcomed the Supreme Court's dismissal of a plea of the Shapoorji Pallonji (SP) group seeking a review of the verdict that upheld the Tata group's removal of Cyrus Mistry as Chairman of Tata Sons. Reacting to the development, in a statement Tata, who is the Chairman Emeritus said, "We would like to express our grateful appreciation o...
Key News - Tata Sons, Dr Reddy's Labs, APM Terminals Pipavav, Maruti Suzuki India, MakeMyTrip , Waaree, By ARETE Securities
Key News - Tata Sons, Dr Reddy's Labs, APM Terminals Pipavav, Maruti Suzuki India, MakeMyTrip , Waaree, By ARETE Securities
Source: ARETE Securities Ltd
20/05/2022 9:23:08 AM
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,800 - Motilal Oswal Efforts on track to sustain robust launches across markets Intensified competition impairs profitability for the quarter * Dr Reddy’s Labs (DRRD)’s 4QFY22 result was below our expectation due to increased price erosion in the US/EU segments, lower export benefits and higher inventory provisions. * We cut our EPS estimates by 6%/8% for FY23/FY24 to factor in: a) divestment of brands in Russia/India, b) lower volume off-take and adverse price variance in key markets of the ...
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,800 - Motilal Oswal
Buy Dr Reddy's Laboratories Ltd For Target Rs.4,800 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
20/05/2022 8:38:22 AM
Dr. Reddy's Labs Q4 net profit up 34.74% at Rs 419.70 cr The company reported standalone net profit of Rs 419.70 crore for the quarter ended March 31, 2022 as compared to Rs 311.50 crore in the same period last year, registering a year-on-year growth of 34.74 per cent. Net revenue of the company rose moderately by 8.39 per cent at Rs 3,631.90 crore in January-March quarter of this fiscal as against Rs 3,350.70 crore in the corresponding period last year. During January-March quarter, operating expenses increased by 9.13 per cent to Rs 2,998.80 c...
Dr. Reddy's Labs Q4 net profit up 34.74% at Rs 419.70 cr
Dr. Reddy's Labs Q4 net profit up 34.74% at Rs 419.70 cr
Source: Dion Global Solutions Ltd
19/05/2022 4:03:09 PM
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,160 - Motilal Oswal Promising outlook; comfortable valuations Multiple drivers to underpin growth over the next 2-3 years Dr. Reddy’s Labs (DRRD) had demonstrated considerable improvement in operating margin (600bp) over FY17-21, despite pricing headwinds in its key US market. However, during 9MFY22, there has been some moderation in margin due to the increased raw-material/supply chain costs, impairing margins in the PSAI segment. We expect DRRD’s earnings growth momentum to sustain over the n...
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,160 - Motilal Oswal
Buy Dr Reddy's Laboratories Ltd For Target Rs.5,160 - Motilal Oswal
Source: Motilal Oswal Financial Services Ltd
1/04/2022 11:37:17 AM
LKP Spade, Weekly Pick - Dr. Reddy's Laboratories Ltd For Target Rs.4230 - LKP Securities Dr. Reddy's Laboratories * On the daily chart, piercing line candlestick pattern has formed which suggests a bullish reversal. . * Volume has been strong as the stock attempts a bullish reversal.A positive divergence is visible on the daily RSI, indicating a bullish momentum in the near term. * Over the near term the stock price may witness a strong recovery towards 4250 as long as it holds 3600 where the multiple lows can be seen on the daily timeframe. Dr. Reddy's La...
LKP Spade, Weekly Pick - Dr. Reddy's Laboratories Ltd For Target Rs.4230 - LKP Securities
LKP Spade, Weekly Pick - Dr. Reddy's Laboratories Ltd For Target Rs.4230 - LKP Securities
Source: LKP Securities Ltd
7/03/2022 10:53:28 AM
Stock Picks - Hindalco Industries Ltd and Dr. Reddy's Laboratories Ltd By ICICI Direct Hindalco Industries Buy Hindalco Industries@ 571.00-573.00 CMP 572.70 TGT 882.50 SL 566.70   Dr. Reddy's Laboratories Buy Dr. Reddy's Laboratories Ltd @ 4068.00-4074.00 CMP 4074.25 TGT 003.00SL 4107.70   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express by all participants are fo...
Stock Picks - Hindalco Industries Ltd and Dr. Reddy's Laboratories Ltd By ICICI Direct
Stock Picks - Hindalco Industries Ltd and Dr. Reddy's Laboratories Ltd By ICICI Direct
Source: ICICI Direct
2/03/2022 11:12:04 AM
Key News - ABG Shipyard Ltd, State Bank of India Ltd , Tata Motors , Oil and Natural Gas Corporation , Dr. Reddy's Laboratories By ARETE Securities Key News ABG Shipyard, its directors booked by CBI in Rs 22,842-cr bank fraud case In its biggest bank fraud case, the CBI has booked ABG Shipyard Ltd and its former chairman and managing director Rishi Kamlesh Agarwal along with others for allegedly cheating a consortium of banks led by State Bank of India of over Rs 22,842 crore, officials said on Saturday Besides Agarwal, the agency has also named the then executive director Santhanam Muthaswamy, directors Ashwini Kumar, Sushil Ku...
Key News - ABG Shipyard Ltd, State Bank of India Ltd , Tata Motors , Oil and Natural Gas Corporation , Dr. Reddy's Laboratories By ARETE Securities
Key News - ABG Shipyard Ltd, State Bank of India Ltd , Tata Motors , Oil and Natural Gas Corporation , Dr. Reddy's Laboratories By ARETE Securities
Source: ARETE Securities Ltd
14/02/2022 9:05:43 AM
Novartis signs exclusive sales and distribution agreement with Dr Reddy's Labs Novartis India Ltd (NIL) on Friday announced an exclusive sales and distribution agreement with Dr. Reddy's Laboratories for a few of its established Medicines which includes the Voveran range, the Calcium range and Methergine. This arrangement aims to further broaden access of these medicines beyond the current geographies to benefit many more patients, more efficiently, by significantly extending the reach of healthcare professionals through an expanded field force. This brings t...
Novartis signs exclusive sales and distribution agreement with Dr Reddy's Labs
Novartis signs exclusive sales and distribution agreement with Dr Reddy's Labs
Source: IANS
12/02/2022 10:04:03 AM
Buy Dr Reddy's Laboratories Ltd For Target Rs.6,100 - Centrum Broking Margins traction sturdy DRRD reported earnings below our estimates, driven by lower PSAI sales and lower other income. The EBITDA margins have been steady for the quarter despite lower contribution from PSAI, steady R&D spend and cost escalations. Gross margins have improved consistently for global generics business, Q3 improvement of 90 bps to 58% sequentially. The product mix, better market-share in key products and better capacity utilisation has contributed to the improving gross m...
Buy Dr Reddy's Laboratories Ltd For Target Rs.6,100 - Centrum Broking
Buy Dr Reddy's Laboratories Ltd For Target Rs.6,100 - Centrum Broking
Source: Centrum Broking Ltd
5/02/2022 11:07:43 AM
Dr. Reddy's Labs Q3 net profit down 23.12% at Rs 341.10 cr The company reported standalone net profit of Rs 341.10 crore for the quarter ended December 31, 2021 as compared to Rs 443.70 crore in the same period last year, registering a year-on-year decline of 23.12 per cent. Net revenue of the company rose marginally by 2.09 per cent at Rs 3,479.60 crore in October-December quarter of this fiscal as against Rs 3,408.20 crore in the corresponding period last year. During October-December quarter, operating expenses increased by 8.78 per cent to Rs 2,8...
Dr. Reddy's Labs Q3 net profit down 23.12% at Rs 341.10 cr
Dr. Reddy's Labs Q3 net profit down 23.12% at Rs 341.10 cr
Source: Dion Global Solution Ltd
28/01/2022 4:12:53 PM
Stock Picks - Dr. Reddy's Laboratories Ltd And TVS Motor Company​​​​​​​​​​​​​​ Ltd By ICICI Direct Dr. Reddy's Laboratories Sell Dr. Reddy's Laboratories Ltd @ 4354.00-4358.00 CMP 4358.00 TGT 4270.20 SL 4401.00   TVS Motor Company Sell TVS Motor Company Ltd @ 611.00-613.00 CMP 613.00 TGT 600.20 SL 618.30   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.html   Views express b...
Stock Picks - Dr. Reddy's Laboratories Ltd And TVS Motor Company​​​​​​​​​​​​​​ Ltd By ICICI Direct
Stock Picks - Dr. Reddy's Laboratories Ltd And TVS Motor Company​​​​​​​​​​​​​​ Ltd By ICICI Direct
Source: ICICI Direct
25/01/2022 10:49:30 AM
Covid antiviral drug Molnupiravir launched in India Covid antiviral drug Molnupiravir was on Monday launched in India at Rs 1,399 for a five-day course for mild to moderate infection. Amid rising cases of new Covid variant Omicron in the country, an expert panel of the Central Drugs Standard Control Organisation had recently approved antiviral drug Molnupiravir for restricted use in emergency situation. Along with Molnupiravir, the CDSCO has also granted emergency use authorisation to the Serum Institute of India's Covid vaccine COVO...
Covid antiviral drug Molnupiravir launched in India
Covid antiviral drug Molnupiravir launched in India
Source: IANS
4/01/2022 4:23:45 PM
Dr Reddy's to soon launch Molnupirvair capsules Dr Reddy's Laboratories, which Tuesday received emergency-use authorisation from the Drugs Controller General of India (DCGI) to manufacture and market the oral anti-viral drug Molnupiravir for treatment of Covid-19, will soon launch its Molnupiravir capsules 200mg under the brand name Molflu across India. The Hyderabad-based company said it received approval from the DCGI to manufacture and market Molnupirvair capsules 200mg for the treatment of adult patients with Covid-19, with SpO2...
Dr Reddy's to soon launch Molnupirvair capsules
Dr Reddy's to soon launch Molnupirvair capsules
Source: IANS
29/12/2021 9:37:39 AM
Indian vaccine makers bank on boosters as demand crashes NEW DELHI  -Indian COVID-19 vaccine makers are lobbying the government to authorise boosters as supplies have so outstripped demand that one drugmaker told Reuters it had suspended a plan to produce more than 100 million doses of Russia's Sputnik shot. The Serum Institute of India (SII), the world's biggest vaccine maker, and Sputnik's Indian distributor, Dr. Reddy's Laboratories, have both said they have approached health authorities about boosters. India has said ...
Indian vaccine makers bank on boosters as demand crashes
Indian vaccine makers bank on boosters as demand crashes
Source: Reuters
8/12/2021 7:19:25 PM
Buy Dr. Reddy’s Laboratories Ltd For Target Rs.5,534 - ICICI Securities Strong margin recovery with scale-up in US sales Dr. Reddy’s Laboratories’ (DRL) Q2FY22 performance was above our estimates on all parameters. Revenue grew 17.7% YoY to Rs57.6bn (I-Sec: Rs52.3bn) driven by strong growth in India & emerging markets as well as scale-up in US sales. Domestic growth was also supported by supplies of Sputnik V vaccine. US sales grew 8.5% QoQ to US$255mn driven by new launches including Vascepa and volume gain in key products. EBITDA margin at 23...
Buy Dr. Reddy’s Laboratories Ltd For Target Rs.5,534 - ICICI Securities
Buy Dr. Reddy’s Laboratories Ltd For Target Rs.5,534 - ICICI Securities
Source: ICICI Securities Ltd
8/12/2021 10:57:14 AM
Stock Picks - Housing Development Finance Corporation Ltd and Dr Reddy’s Laboratories​​​​​​​ Ltd By ICICI Direct Housing Development Finance Corporation Buy Housing Development Finance Corporation Ltd @ 2768.00-2774.00 CMP 2771.60 TGT 2824.00 SL 2742.40   Dr Reddy’s Laboratories Sell Dr Reddy’s Laboratories Ltd @ 4506.00-4512.00 CMP 4504.95 TGT 4426.60 SL 4554.30​​​​​​​   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/Sta...
Stock Picks - Housing Development Finance Corporation Ltd and Dr Reddy’s Laboratories​​​​​​​ Ltd By ICICI Direct
Stock Picks - Housing Development Finance Corporation Ltd and Dr Reddy’s Laboratories​​​​​​​ Ltd By ICICI Direct
Source: ICICI Direct
7/12/2021 11:40:56 AM
Stock Picks - Larsen & Toubro Infotech​​​​​​​ Ltd and Dr Reddy’s Laboratories Ltd By ICICI Direct Larsen & Toubro Infotech Buy Larsen & Toubro Infotech Ltd @ 6918.00-6925.00 CMP 6938.60 TGT 7019.00 SL 6869.30   Dr Reddy’s Laboratories Sell Dr Reddy’s Laboratories Ltd @ 4620.00-4626.00 CMP 4623.05 TGT 4561.00 SL 4656.30​​​​​​​   To Read Complete Report & Disclaimer Click Here   https://secure.icicidirect.com/Content/StaticData/Disclaimer.htm...
Stock Picks - Larsen & Toubro Infotech​​​​​​​ Ltd and Dr Reddy’s Laboratories Ltd By ICICI Direct
Stock Picks - Larsen & Toubro Infotech​​​​​​​ Ltd and Dr Reddy’s Laboratories Ltd By ICICI Direct
Source: ICICI Direct
2/12/2021 11:56:01 AM